Type of Therapy | Agents/Agent combinations |
---|---|
Traditional Chemotherapies | |
 Platinum monotherapy | Carboplatin, Cisplatin |
 Platinum doublet therapy | |
  With cisplatin | Docetaxel, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, Vinorelbine |
  With carboplatin | Docetaxel, Gemcitabine, Paclitaxel, Pemetrexed, Vinorelbine |
 Non-platinum based combination therapies | Gemcitabine/Docetaxel, Gemcitabine/Paclitaxel, Gemcitabine/Vinorelbine, Paclitaxel/Vinorelbine, Pemetrexed/Gemcitabine |
 Maintenance therapy | Docetaxel, Gemcitabine, Pemetrexed |
Immunotherapies | Atezolizumab, Nivolumab, Pembrolizumab |
Targeted Therapies | |
 ALK inhibitors | Alectinib, Brigatinib, Ceritinib, Crizotinib |
 Angiogenesis inhibitors | Bevacizumab, Ramucirumab |
 BRAF inhibitor | Vemurafenib |
 CDK4/6 inhibitor | Palbociclib |
 EGFR monoclonal antibody inhibitor | Cetuximab, Necitumumab |
 EGFR tyrosine kinase inhibitors | Afatinib, Erlotinib, Gefitinib, Osimertinib |
 MEK inhibitor | Trametinib |
 Other monoclonal antibody inhibitors | Ipilimumab, Trastuzumab |